Do you want to read an article? Please log in or register.
Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the Omicron dominant era
Respiratory Tract Infection
Related content
RECOMMENDED
ARDSPneumonia
Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
van der Ven FLIM, Blok SG, Azevedo LC, Bellani G, Botta M, Estenssoro E, Fan E, Ferreira JC, Laffey JG, Martin-Loeches I, Motos A, Pham T, Peñuelas O, Pesenti A, Pisani L, Neto AS, Schultz MJ, Torres A, Tsonas AM, Paulus F, van Meenen DMP, ERICC–, LUNG SAFE–, PRoVENT–COVID–, EPICCoV–, CIBERESUCICOVID–, SATI–COVID–19–investigators
doi: 10.1186/s12931-024-02910-2
Respiratory Tract Infection
Adiposity and mortality among intensive care patients with COVID-19 and non-COVID-19 respiratory conditions: a cross-context comparison study in the UK
BMC Med
Bell JA, Carslake D, Hughes A, Tilling K, Dodd JW, Doidge JC, Harrison DA, Rowan KM, Davey Smith G
doi: 10.1186/s12916-024-03598-3
RECOMMENDED
Asthma
Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Papaioannou O, Christopoulos I, Tsiri P, Sampsonas F, Karkoulias K, Lykouras D, Sotiropoulou V, Theohari E, Papalexatos D, Komninos D, Christopoulos A, Tzouvelekis A
doi: 10.3390/jcm14072174
Pulmonary Hypertension
A real-world comparative effectiveness analysis of macitentan versus ambrisentan and bosentan on hospitalizations and healthcare resource utilization in patients with pulmonary arterial hypertension
Respir Med
Paoli CJ, Zhang C, Tang X, Panjabi S, Thompson A, El-Kersh K
doi: 10.1016/j.rmed.2025.108112
PneumoniaRespiratory Tract Infection
Effect of the Covid-19 pandemic on hospitalizations for non-Covid-19-pneumonia and exacerbations of chronic obstructive pulmonary diseases in Switzerland: comparison of national data between 2020/2021 and 2015-2019
Pneumonia (Nathan)
Bürke C, Baty F, Rassouli F, Brutsche MH, Albrich WC
doi: 10.1186/s41479-024-00150-y
Lung Cancer
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC
Clin Lung Cancer
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C
doi: 10.1016/j.cllc.2025.05.007
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
RECOMMENDED
Asthma
Key Characteristics of Asthma Patients with COVID-19 Vary Substantially by Age
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Asthma Allergy
Kirui BK, Santosa A, Li H, Vanfleteren LEGW, Stridsman C, Nyberg F
doi: 10.2147/JAA.S456145
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015